We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tissue Regenix Group Plc | LSE:TRX | London | Ordinary Share | GB00BNTXR104 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -0.81% | 61.00 | 61.00 | 62.00 | 61.50 | 61.50 | 61.50 | 59,347 | 16:35:16 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 29.49M | -302k | -0.0043 | -143.02 | 43.4M |
Date | Subject | Author | Discuss |
---|---|---|---|
11/5/2015 12:38 | Yes, I agree with the above.It's as comforting as one of its dermapure products that it hasn't fallen back today after a widening FY loss. The accompanying RNS about the further two states shows that the direction of travel is good. If one of the clinical trials comes good then we could easily double from here. Well funded currently so it is just important that TRX maximises revenue to avoid the need for another placing at the end of the year. | mach100 | |
11/5/2015 11:28 | Well I've added on that statement,overheads are going to be expensive at this stage so not worried.If we do drift a bit will continue to add. | samenic | |
11/5/2015 09:51 | Phew as in no bad news : I feared that the drip drip last week of good news meant there was bad news in the results today. | igbertsponk | |
11/5/2015 09:49 | Phew? As in the market doesn't like it? | rayrac | |
11/5/2015 08:29 | No big baddies in there. Fairly positive all the way through. Phew ! | igbertsponk | |
11/5/2015 07:27 | That's a given bamboo! Costs cannot be controlled at this stage. Income will come, sooner the better, hopefully before a predator appears? | rayrac | |
10/5/2015 21:50 | contact2, given that these are to be the results for the year ended 31 January 2015, there will probably be no income at all. However, we will hopefully get an update that may include news of initial sales after this period. I'm guessing that we are just about ready to move on from the 'free sample' stage. Interim results from the stage iv clinical trial are possible next month. | bamboo2 | |
10/5/2015 18:16 | There was a £3 m plus loss in the last six months. Costs had escalated to facilitate staff in the US.I hope the next results show that sales will be begin to cover these costs. The recent announcement of sales in the next 12 months of £400,000 will be a pebble in the ocean if costs are not controlled. | contact2fsnetcouk | |
09/5/2015 21:03 | bamboo2. I doubt I can add much - if anything - to your own in-depth knowledge (or informed, albeit back of envelope, guesswork) regarding the results. I don't believe there will be much in terms of historic financial or developmental events which we don't know already. Similarly, the immediate future is fairly well flagged in terms of plans to develop the sales pipeline and the research processes. However, I hope that the forward looking (outlook) statement will provide some positive and detailed guidance on the progress on sales for the more "oven-ready products" such as Dermapure and on the approval processes and trials on the products which are in the "mixing bowls" or just in the "recipe books". Up early on Monday morning in anticipation of an interesting RNS. | grahamburn | |
08/5/2015 13:57 | Ray TRX for a pound or more ! Here for the long term. CPX - whatever I can get in the mid/high teens if it goes crazy again - but 10p would be pretty good too. | luminoso | |
08/5/2015 10:21 | Results Monday. grahamburn, what are your expectations, if any? btw, my earlier extrapolation was 'back of an envelope' | bamboo2 | |
06/5/2015 23:40 | TRX or CPX? Easily obtainable here, but 10p might be pushing it at the other, but who knows? | rayrac | |
06/5/2015 16:47 | Personally, I am hoping for a pound or more one day. | luminoso | |
06/5/2015 14:12 | Held this for years. Seems to be waking up again. We hoping for 25-30 again? | maccamcd | |
06/5/2015 12:49 | Bam, no, quite recent. I'm in there for a risky punt, aware of course, of its bod etc! (Aussie) | rayrac | |
06/5/2015 10:08 | bamboo, I think the hype and madness at CPX could carry it way over 13p in next few weeks. The placing seems to be a relatively small one and i think will be swallowed up quickly. One never knows when the herd are involved, as it goes in all directions ...fast ! | luminoso | |
06/5/2015 10:01 | Ditto, Ray. I am in CPX too but have been trading it until the placement sorted, whereas here I am a ltbh. Horses for courses. | luminoso | |
06/5/2015 08:21 | Three trading days to the results. I was looking forward to some news with the results, but it seems like we might have had it all already. Good to see the share price back at placing level. o/t Ray, I have looked at the CPX chart and find it difficult to work out a price target, although looking at past history and the trendlines, 13p could be on the cards. The tech looks interesting, have you been holding for long? | bamboo2 | |
05/5/2015 19:27 | We will have to post more often on this thread...get message out to the pi's! It helps ya know. Actually I do hold some Cap-xx, bought @ 2.395p.😜 going to hold on to that one (as here at TRX). They talk of it being another ARM. Ha ha ho ho. But we shall see? | rayrac | |
05/5/2015 14:17 | When TRX takes off in the future, you will inevitably get the crowd here. No harm in that for our bank balances. Although CAP-xx is very different, thankfully. | luminoso | |
05/5/2015 13:52 | Heaven help us if we ever get to the hype surrounding such a share as CAP-XX. Just look at its share price behaviour today! Steady long term appreciation is much preferred in my opinion - supported by a quiet and rational discussion board. | grahamburn | |
05/5/2015 13:46 | Wish this had the same 'mad' following as Cap-xx! I think TRX deserves it. At least Wooford believes it, otherwise he wouldn't hold so many. | rayrac |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions